ASTRAZENECA SECURES NHS ACCESS TO IMFINZI▼(DURVALUMAB

Imfinzi (durvalumab) in combination with gemcitabine and cisplatin (chemotherapy) has been recommended by the National Institute for Health and Care Excellence (NICE) for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer (BTC).1Durvalumab is AstraZeneca UK&rsq...

Related Keywords

Manchester , United Kingdom , London , City Of , Great Britain , Helen Morement , Ptom Keith Roach , David Brocklehurst , Cholangiocarcinoma Charity , Senior Lecturer University Of Manchester , National Institute For Health , Astrazeneca , National Institute , Care Excellence , Astrazeneca United Kingdom , Senior Lecturer , Honorary Consultant , Innovation Passport , Innovative Licensing , Access Pathway ,